A Phase 2a, randomized, double blind, placebo controlled study of PRO 140 by subcutaneous administration in adult subjects with human immunodeficiency virus type 1 infection

Trial Profile

A Phase 2a, randomized, double blind, placebo controlled study of PRO 140 by subcutaneous administration in adult subjects with human immunodeficiency virus type 1 infection

Completed
Phase of Trial: Phase II

Latest Information Update: 15 Dec 2015

At a glance

  • Drugs PRO 140 (Primary)
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Sponsors Progenics Pharmaceuticals
  • Most Recent Events

    • 08 Apr 2010 Results published in Journal of infectious diseases.
    • 16 Sep 2009 Actual end date (Nov 2008) added as reported by ClinicalTrials.gov.
    • 16 Sep 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top